Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
A phase 1/2 trial of Obinutuzumab, Pembrolizumab in melanoma and renal cell carcinoma, run by Simcha IL-18, Inc., now recruiting.
Overview
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 is a phase 1/2 interventional study registered as NCT04787042 by Simcha IL-18, Inc., with 316 participants planned, started 2021-08-06 and due to reach its primary completion in 2025-06-30. Interventions recorded: ST-067, Obinutuzumab 25 MG/1 ML Intravenous Solution [GAZYVA], pembrolizumab. Conditions listed: Cancer, Solid Tumor, Melanoma, Renal Cell Carcinoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrol
Shares Renal cell carcinoma, Melanoma, Pembrolizumab, Small-cell lung cancer.
- TrialA Study of NDI 1150-101 in Patients With Solid Tumors
Shares Renal cell carcinoma, Pembrolizumab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Beta-only IL-2 ImmunoTherapY Study
Shares Renal cell carcinoma, Pembrolizumab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialStudy of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalen
Shares Renal cell carcinoma, Melanoma, Pembrolizumab, Small-cell lung cancer.
- TrialSafety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
Shares Renal cell carcinoma, Melanoma, Pembrolizumab, Small-cell lung cancer.
- TrialGM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors
Shares Renal cell carcinoma, Melanoma, Pembrolizumab.
- TrialA Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
Shares Renal cell carcinoma, Melanoma, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialPh I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors
Shares Renal cell carcinoma, Pembrolizumab, Small-cell lung cancer, Non-small-cell lung cancer.